The announcement of expected increased expenses in R&D and SG&A for Krystal Biotech could lead to concerns about short-term profitability and cash flow, potentially putting downward pressure on the stock price in the short term. However, this investment could be viewed positively in the long term if it leads to successful product development and market expansion.